Cross-Reactive Immune Response of Bovine Coronavirus Spike Glycoprotein to SARS-CoV-2 Variants of Concern
International Journal of Molecular Sciences · 26.10.2024 · 25 (21) · 11509
DOI: 10.3390/ijms252111509 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 26.10.2024. Verfasst von Chiara Cossu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Biotechnology Center "Guido Tarone", Department of Molecular Biotechnology and Health Sciences, University of Turin, Piazza Nizza 44, 10126…. Hauptthemen laut MEDLINE: Spike Glycoprotein, Coronavirus, Cross Reactions, SARS-CoV-2, Coronavirus, Bovine. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: This research was funded by University of Torino and by University of Parma through "Finan-ziamento dell'Unione Europea-Next generation EU-PRIN-2022/PNRR, University of Parma.
Abstract (Originalsprache)
The high variability observed in the clinical symptoms of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections has been attributed to the presence, in a proportion of infection-naive subjects, of pre-existing cross-reactive immune responses. Here, we demonstrate that the bovine coronavirus spike protein (BoS) may represent a source of protective immunity to SARS-CoV-2. Indeed, vaccination of BALB/c mice with a Bovine herpesvirus 4 (BoHV-4)-based vector expressing BoS induced both cell-mediated and humoral immune responses that cross-react with SARS-CoV-2 spike protein. Although the spike-specific antibodies induced by BoS did not neutralize SARS-CoV-2, the T lymphocytes activated by BoS were able to induce cytotoxicity of cells expressing spike proteins derived from several SARS-CoV-2 variants. These results demonstrate that immunization with BoS may represent a source of cross-reactive immunity to SARS-CoV-2, and that these cross-reactive immune responses may exert protective functions. These results contribute to deciphering the mechanisms responsible for lack or mildness of symptoms observed in many individuals upon SARS-CoV-2 infection and may open new ways for the development of new vaccines for coronaviruses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Biotechnology Center "Guido Tarone", Department of Molecular Biotechnology and Health Sciences, University of Turin, Piazza Nizza 44, 10126 Turino, Italy.
- Department of Veterinary Science, University of Parma, 43126 Parma, Italy.
ORCID-Profile: Valentina Franceschi, Antonino Di Lorenzo, Sergio Minesso, Laura Conti, Gaetano Donofrio
Förderung
- This research was funded by University of Torino and by University of Parma through "Finan-ziamento dell'Unione Europea-Next generation EU-PRIN-2022/PNRR
- University of Parma
Zitieren
APA
Cossu, C., Franceschi, V., Di Lorenzo, A., Bolli, E., Minesso, S., Cotti, C., Conti, L., & Donofrio, G. (2024). Cross-Reactive Immune Response of Bovine Coronavirus Spike Glycoprotein to SARS-CoV-2 Variants of Concern. International Journal of Molecular Sciences, 25(21), 11509. https://doi.org/10.3390/ijms252111509
Vancouver
Cossu C, Franceschi V, Di Lorenzo A, Bolli E, Minesso S, Cotti C, et al. Cross-Reactive Immune Response of Bovine Coronavirus Spike Glycoprotein to SARS-CoV-2 Variants of Concern. International Journal of Molecular Sciences. 2024;25(21):11509. doi:10.3390/ijms252111509
BibTeX
@article{Cossu2024,
author = {Cossu, Chiara and Franceschi, Valentina and Di Lorenzo, Antonino and Bolli, Elisabetta and Minesso, Sergio and Cotti, Camilla and Conti, Laura and Donofrio, Gaetano},
title = {Cross-Reactive Immune Response of Bovine Coronavirus Spike Glycoprotein to SARS-CoV-2 Variants of Concern},
journal = {International Journal of Molecular Sciences},
year = {2024},
volume = {25},
number = {21},
pages = {11509},
doi = {10.3390/ijms252111509}
}
EUVIMED